NorthStrive transfers EL-32 cell bank to US facility for manufacturing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in C
April 13, 2026 7:30 AM EDTNEWPORT BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (NorthStrive Biosciences), a wholly owned subsidiary of PMGC Holdings Inc. (PMGC or the Company) (NASDAQ: ELAB), today announced a key development milestone for its asset, EL-32: the successful transfer of the EL-32 Working Cell Bank (WCB) to a U.S.-based third-party fermentation facility. This transfer initiates a manufacturing optimization program designed to increase production yield and establish a cost-efficient, scalable process in support of future clinical and commercial development.
EL-32 is a dual-action engineered probiotic therapeutic designed to express both myostatin and activin-A... More
